Ascletis Eyes Launch Of China’s First Oral HCV Drug, Possible IPO

Already well-funded Chinese venture Ascletis has completed a large Series B to support the commercialization of effective new oral HCV drugs and progress its pipeline, and has not ruled out the possibility of going public in an IPO.